Wildcat Capital Management LLC increased its position in MiMedx Group, Inc (NASDAQ:MDXG) by 27.9% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 500,000 shares of the medical equipment provider’s stock after buying an additional 109,000 shares during the period. MiMedx Group comprises 1.1% of Wildcat Capital Management LLC’s portfolio, making the stock its 8th largest holding. Wildcat Capital Management LLC owned approximately 0.45% of MiMedx Group worth $5,940,000 at the end of the most recent quarter.
Several other large investors have also recently bought and sold shares of MDXG. Teachers Advisors LLC raised its position in shares of MiMedx Group by 2.4% in the first quarter. Teachers Advisors LLC now owns 214,141 shares of the medical equipment provider’s stock valued at $2,041,000 after buying an additional 5,114 shares during the last quarter. Schwab Charles Investment Management Inc. raised its position in shares of MiMedx Group by 5.8% in the first quarter. Schwab Charles Investment Management Inc. now owns 419,315 shares of the medical equipment provider’s stock valued at $3,997,000 after buying an additional 23,037 shares during the last quarter. Credit Suisse AG grew its holdings in MiMedx Group by 14.6% in the first quarter. Credit Suisse AG now owns 153,040 shares of the medical equipment provider’s stock valued at $1,458,000 after purchasing an additional 19,454 shares during the period. Aperio Group LLC grew its holdings in MiMedx Group by 32.2% in the second quarter. Aperio Group LLC now owns 26,211 shares of the medical equipment provider’s stock valued at $392,000 after purchasing an additional 6,382 shares during the period. Finally, Russell Investments Group Ltd. grew its holdings in MiMedx Group by 20.9% in the second quarter. Russell Investments Group Ltd. now owns 363,947 shares of the medical equipment provider’s stock valued at $5,449,000 after purchasing an additional 62,972 shares during the period. 69.36% of the stock is owned by institutional investors and hedge funds.
Shares of MiMedx Group, Inc (NASDAQ:MDXG) opened at $11.75 on Monday. MiMedx Group, Inc has a twelve month low of $7.64 and a twelve month high of $17.47. The stock has a market cap of $1,304.66, a P/E ratio of 55.95, a P/E/G ratio of 2.98 and a beta of 0.87.
MiMedx Group (NASDAQ:MDXG) last released its earnings results on Thursday, October 26th. The medical equipment provider reported $0.08 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.08. MiMedx Group had a net margin of 11.64% and a return on equity of 17.49%. The firm had revenue of $84.60 million during the quarter, compared to the consensus estimate of $84.60 million. During the same period in the previous year, the firm earned $0.06 earnings per share. MiMedx Group’s revenue was up 31.4% compared to the same quarter last year. analysts forecast that MiMedx Group, Inc will post 0.23 EPS for the current fiscal year.
MiMedx Group announced that its board has initiated a stock repurchase program on Monday, October 9th that allows the company to buyback $10.00 million in shares. This buyback authorization allows the medical equipment provider to purchase shares of its stock through open market purchases. Stock buyback programs are typically an indication that the company’s leadership believes its shares are undervalued.
A number of equities research analysts recently issued reports on the stock. Piper Jaffray Companies restated a “buy” rating and issued a $18.00 target price on shares of MiMedx Group in a report on Sunday, August 20th. Needham & Company LLC restated a “buy” rating and issued a $21.00 target price on shares of MiMedx Group in a report on Friday, December 1st. Zacks Investment Research downgraded shares of MiMedx Group from a “hold” rating to a “sell” rating in a report on Wednesday, October 4th. Finally, BidaskClub downgraded shares of MiMedx Group from a “buy” rating to a “hold” rating in a report on Saturday, August 26th. Three analysts have rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the stock. MiMedx Group has a consensus rating of “Hold” and a consensus target price of $15.40.
TRADEMARK VIOLATION NOTICE: This article was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this article on another website, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2017/12/11/mimedx-group-inc-mdxg-shares-bought-by-wildcat-capital-management-llc.html.
MiMedx Group Company Profile
MiMedx Group, Inc is an integrated developer, processor and marketer of regenerative biomaterial products and bioimplants human placental tissue, skin and bone. The Company’s Regenerative Biomaterials segment includes the design, manufacture, and marketing of products and tissue processing services for the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental market categories.
Want to see what other hedge funds are holding MDXG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MiMedx Group, Inc (NASDAQ:MDXG).
Receive News & Ratings for MiMedx Group Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiMedx Group Inc and related companies with MarketBeat.com's FREE daily email newsletter.